Clinical trials: Hepatitis Delta Virus
Hepatitis B, Hepatitis C
Epidemiology of Hepatitis B, C and D and HIV Along the Maroni River Bordering French Guiana and Suriname (MaHeVi)
MaHeVi is a multicenter, cross-sectional, population-based study which will include 2500 adults in the health care centers / missions located on the 2 sides of the Maroni River.
- Conditions
- Hepatitis B, Hepatitis C, Hepatitis D, HIV Infections
- Trial name
- MaHeVi (NCT05002907)
- Testing
- Questionnaire, Biocollection, Delivery of results
- Where
- 2 sites in French Guiana, Suriname
- Volunteers
- 2,289 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier de Cayenne
HDV
Thailand HDV Cohort
There is very limited data of HDV in Thailand. As both HDV and HIV can accelerate the HBV course and increased the risk of death, particularly, among those with low CD4 cells/count, therefore, HDV burden in this special…
- Trial name
- NCT05350865
- Where
- 4 sites in Thailand
- Volunteers
- 3,296 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
Hepatitis D, Chronic
A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.
This randomized, single blind study will compare the antiviral effect of Pegasys (pegylated interferon alfa-2a) plus placebo versus Pegasys plus tenofovir in patients with chronic hepatitis D.
- Trial name
- NCT01088659
- Testing
- peginterferon alfa-2a [Pegasys], tenofovir
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis D Infection
A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
This is a Phase 3, global, randomized, open-label, multicenter, trial evaluating brelovitug (BJT-778) vs bulevirtide for the treatment of chronic hepatitis delta infection (CHD).
- Trial name
- NCT07200908
- Testing
- Brelovitug 300 mg, Bulevirtide 2 mg and Brelovitug - 300 mg
- Where
- 57 sites in Austria, Czechia and 10 more
- Volunteers
- 172 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Chronic Hepatitis D
Burden of Hepatitis D Virus (HDV) Infection in Italy
The circulation of the Hepatitis D Virus (HDV) has considerably diminished in Italy, secondary to the control of the Hepatitis B Virus (HBV) with vaccination; this has led to the perception that HDV is vanishing and has reduced…
- Trial name
- HDV Describe (NCT05723068)
- Where
- 36 sites in Italy
- Volunteers
- 515 people
- Sponsor
- University of Turin, Italy
Chronic Delta Hepatitis
A Study of Lonafarnib With or Without Ritonavir in Patients With HDV
A Phase 2b, Open-Label, Randomized Study of the Safety, Tolerability, and Pharmacodynamic Activity of Lonafarnib With or Without Ritonavir in Patients Chronically Infected with Hepatitis Delta Virus
- Trial name
- LOWR-5 (NCT02968641)
- Testing
- Lonafarnib, Ritonavir
- Sponsor
- Eiger BioPharmaceuticals
Chronic Hepatitis Delta
Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)
The primary objective of this study is to evaluate the efficacy of bulevirtide administered subcutaneously (SC) for 48 weeks at a dose of 2 mg or 10 mg once daily for treatment of chronic hepatitis delta (CHD) in comparison to…
- Trial name
- NCT03852719
- Testing
- Bulevirtide
- Where
- 19 sites in United States, Germany and 3 more
- Volunteers
- 150 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis B, Acute Hepatitis B
Disease Loads and Status of Treatment
The aim of study is to evaluate the current prevalence of HDV infection, and comprehensively analyze the interaction between HDV and HBV infections in the era of NAs in Taiwan.
- Conditions
- Chronic Hepatitis B, Acute Hepatitis B, Hepatitis D
- Trial name
- NCT05264272
- Testing
- Prospective serological assays, Retrospective serological assays
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Hepatitis D Virus Infection
HDV Screening Study
This is a territory-wide cross-sectional study of all individuals living with HIV/HBV coinfection and HBV-related HCC.
- Trial name
- NCT06889805
- Where
- Hong Kong
- Volunteers
- 300 people
- Sponsor
- Grace Lai Hung Wong
Viral Hepatitis B, Viral Hepatitis D
Replicor Compassionate Access Program
The goal of this compassionate access program is to provide early access to REP 2139-Mg for patients with HBV mono-infection or HBV / HDV co-infection who either have advanced (decompensated) cirrhosis or who have failed to…
- Conditions
- Viral Hepatitis B, Viral Hepatitis D, Cirrhosis, Liver, Decompensated Cirrhosis
- Trial name
- RCAP (NCT05683548)
- Testing
- REP 2139-Mg, Tenofovir Disoproxil Fumarate, Pegylated interferon alpha2a
- Where
- 13 sites in Austria, France and 3 more
- Sponsor
- Replicor Inc.
Hepatitis D, Chronic
Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection
Open label, single arm, multi-center clinical trial of lonafarnib 50 mg QD plus ritonavir 200 mg QD, administered orally, over a 48-week treatment period, with a 24-week post-treatment follow-up period, in patients with chronic…
- Trial name
- LOWR6 (NCT05229991)
- Testing
- Lonafarnib, Ritonavir
- Where
- 3 sites in Israel, New Zealand and 1 more
- Volunteers
- 10 people
- Sponsor
- Soroka University Medical Center
Hepatitis D
Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis
Retrospective and prospective, pharmacological, multicentre, non-profit observational study. Consecutive patients with HDV-related compensated cirrhosis starting Bulevirtide 2 mg/day from September 2019 to December 2025 will be…
- Trial name
- SAVE-D (NCT06397859)
- Testing
- Bulevirtide
- Where
- Italy
- Volunteers
- 266 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Hepatitis D
Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)
Multicenter pharmacological observational prospective, no-profit, study. This study was designed to get a "real-life" snapshot across several Italian Hepatology centers.
- Trial name
- D-SHIELD (NCT06122285)
- Testing
- Bulevirtide
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Human Immunodeficiency Virus, HBV
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
A cohort of adults with HIV-HBV co-infection will be created in Lusaka, Zambia, to describe the short and long-term (up to 10 years of follow-up) HBV and liver outcomes, including the effectiveness of current therapies, and to…
- Conditions
- Human Immunodeficiency Virus, HBV, Fibrosis, Liver, Cirrhosis, Liver
- Trial name
- NCT02344680
- Testing
- Anti-HIV Agents
- Where
- Zambia
- Volunteers
- 349 people
- Sponsor
- University of Alabama at Birmingham
Chronic Hepatitis B
Change of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDF
In Chronic hepatitis B (CHB) patients receiving long-term sequential Neucleos(t)ides(NAs), majority of these CHB patients experienced drug resistance and switched to Tenofovir disoproxil fumaratate(TDF).
- Trial name
- SWITAF (NCT03356834)
- Testing
- Tenofovir alafenamide(TAF), Tenofovir disoproxil fumarate(TDF)
- Where
- Hong Kong
- Volunteers
- 575 people
- Sponsor
- Humanity and Health Research Centre
Hepatic Insufficiency
Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment
The primary objectives were: To determine the effects of steady state TPV co-administered with low dose RTV on steady state PegIFN and RBV in HIV negative subjects with mild hepatic impairment (scheme A) To determine the effects…
- Trial name
- NCT02259855
- Testing
- Tipranavir, Ritonavir, Pegylated interferon
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Hepatitis D Virus Infection
MIGrant Reflex Test HDV (MIGRED) Project
Our research team has executed a robust strategy to improve viral hepatitis detection and linkage to care in migrants, contributing to the improvement of knowledge on the clinical and virological future of viral hepatitis in this…
- Trial name
- NCT06539052
- Testing
- anti-HDV positive with the reflex testing methodology
- Volunteers
- 7,500 people
- Sponsor
- University of Campania Luigi Vanvitelli
Hepatitis D
The Hepatitis Delta International Network
Hepatitis delta is a major health problem, not only because of the severity of the disease, but also due to the lack of effective antiviral treatment.
- Trial name
- HDIN (NCT02375906)
- Where
- 18 sites in Austria, Belgium and 10 more
- Volunteers
- 2,000 people
- Sponsor
- HepNet Study House, German Liverfoundation
Chronic Hepatitis Delta
Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)
The primary objective of this study is to evaluate the efficacy of bulevirtide in combination with pegylated interferon in participants with chronic hepatitis delta (CHD).
- Trial name
- NCT03852433
- Testing
- Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa)
- Where
- 20 sites in France, Moldova and 2 more
- Volunteers
- 175 people
- Sponsor
- Gilead Sciences
Hepatitis D, Chronic
SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.
This is a phase 2 trial in which participants with chronic hepatitis D virus (HDV) infection will receive VIR-2218 and/or VIR-3434 and be assessed for safety, tolerability, and efficacy
- Trial name
- NCT05461170
- Testing
- VIR-2218, VIR-3434, NRTI
- Where
- 20 sites in Bulgaria, France and 7 more
- Volunteers
- 95 people
- Sponsor
- Vir Biotechnology, Inc.